Last night, December 1st, Vancouverite Harvey Lalach‘s most successful stock promotion ever, Anavex (AVXL), lovingly known here as scAmavex, finally revealed long awaited, and amazingly laughable, data from their trial of blarcarmasine (aka Anavex2-73) in Alzheimer’s Disease.
As befitting a filthy reverse merger bioturd, the presentation was so laughable, the results so ludicrous, the accompanying press release so misleading that it was sure to generate intense criticism. So much so that the company quickly removed the slides from their website.
So please consider yourselves lucky, dear readers, as we have the original slide deck preserved for posterity right here.
One can only wonder what Sandra and Nell think about all of this.
THE CONTENT CONTAINED IN THIS BLOG REPRESENTS ONLY THE OPINIONS OF THE AUTHOR. THE AUTHOR MAY HOLD EITHER LONG OR SHORT POSITIONS IN SECURITIES OF VARIOUS COMPANIES DISCUSSED IN THE BLOG. THIS COMMENTARY IN NO WAY CONSTITUTES INVESTMENT ADVICE, AND SHOULD NEVER BE RELIED ON IN MAKING AN INVESTMENT DECISION, EVER. THIS BLOG IS NOT A SOLICITATION OF BUSINESS: ALL INQUIRIES WILL BE IGNORED. THE CONTENT HEREIN IS INTENDED SOLELY FOR THE ENTERTAINMENT OF THE READER, AND THE AUTHOR.